The raw materials and tablets of aripiprazole, a new class 3.1 drug of Enhua Pharmaceutical Co., Ltd., will be inspected on site
-
Last Update: 2020-04-03
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
On May 29, information on the website of the State Food and Drug Administration (CFDA) showed that the raw materials and tablets of aripiprazole, a class 3.1 new drug of Enhua Pharmaceutical Co., Ltd., would enter the site for inspection According to the progress of new drug approval, it is expected to be approved for listing within this year Aripiprazole is a new atypical antipsychotic drug, which was listed in China in 2004 Due to the remarkable curative effect on the positive and negative symptoms of schizophrenia, the products grow rapidly after being put on the market The compound growth rate of the drug was 41.16% in 2006-2010, and the domestic market scale was about 400 million by 2010 According to CFDA, at present, Zhejiang Otsuka, Chengdu Kanghong and Chinese and Western pharmaceutical enterprises have obtained approval documents for pharmaceutical production At the same time, in addition to the Enhua pharmaceutical industry, there are also enterprises such as Huahai pharmaceutical, Qilu pharmaceutical and hausen pharmaceutical in R & D Enhua pharmaceutical industry is the leader of central nervous system medicine in China Last year, the company's main products, midazolam and risperidone, were affected by the administrative price cut, which slowed down the company's industrial growth The market hopes that the company's reserve varieties will be approved for listing and create new performance growth points
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
